A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT

Inclusion Criteria: 1. Ability to understand and willingness to sign written informed consent; 2. Age 14 to 65 years; 3. Diagnosis of sclerotic chronic graft-versus-host disease (scl-cGVHD) according to the 2014 NIH consensus criteria, including superficial or deep skin sclerosis, fasciitis, or restricted joint mobility; 4. Prior treatment history meeting at least one of the following: * Received systemic corticosteroid therapy for ≥12 months and at least 1 additional systemic therapy; OR * Received corticosteroid therapy and at least 2 additional systemic therapies; 5. Karnofsky Performance Status (KPS) score ≥60; 6. Absolute neutrophil count \>1,000/μL; 7. Platelet count ≥50,000/μL. Exclusion Criteria: * 1\. Total bilirubin \>1.5 times the upper limit of normal; 2. Creatinine clearance \<30 mL/min; 3. Uncontrolled infection; 4. Uncontrolled cardiovascular or pulmonary disease; 5. Any clinical condition that, in the investigator's judgment, makes the participant unsuitable for study participation.